This is a non-core endpoint: only basic statistics are computed.
See its core counterpart C3_PANCREAS_NEUROENDOCRINE_EXALLC for full statistics.
Neuroendocrine tumor and carcinoma of pancreas
C3_PANCREAS_NEUROENDOCRINE
No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
199 |
4. Check minimum number of eventsNone |
199 |
5. Include endpointsNone |
199 |
6. Filter based on genotype QC (FinnGen only) |
199 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- First used in FinnGen datafreeze
- DF8
Similar endpoints
↥List of similar endpoints to
Neuroendocrine tumor and carcinoma of pancreas
based on the number of shared cases.
Similar with more cases:
- Neuroendocrine tumor and carcinoma of pancreas, excluding all cancers (controls excluding all cancers)
- Malignant neoplasm of pancreas
- Malignant neoplasm of pancreas, excluding all cancers (controls excluding all cancers)
- Malignant neoplasm of digestive organs
- Malignant neoplasm of digestive organs, excluding all cancers (controls excluding all cancers)
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 199 | 94 | 105 |
| Unadjusted period prevalence (%) | 0.04 | 0.03 | 0.05 |
| Median age at first event (years) | 61.51 | 59.71 | 63.12 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 179
- Matched controls
- 1789
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D37.7
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Other digestive organs
254.8
117.2
110
11
C25.4
ICD-10 Finland
Malignant neoplasm: Endocrine pancreas
1209.8
81.0
73
*
130
Kela drug reimbursment
Malignant tumour
24.5
63.3
97
82
8240/3-C25.9
ICD-O-3
Neuroendocrine tumor, NOS, of pancreas, NOS
+∞
62.1
56
*
A09AA02
ATC
multienzymes (lipase, protease etc.)
72.5
53.0
59
12
H01CB03
ATC
lanreotide; parenteral
643.6
51.1
48
*
JLC10
NOMESCO Finland
Distal pancreatectomy
+∞
49.3
45
*
8249/3-C25.9
ICD-O-3
Neuroendocrine tumor, grade 2 of pancreas, NOS
+∞
48.1
44
*
L01AX03
ATC
temozolomide; systemic
+∞
45.8
42
*
C25.9
ICD-10 Finland
Malignant neoplasm: Pancreas, unspecified
126.1
45.3
47
5
133
Kela drug reimbursment
Severe chronic pancreatic insufficiency
62.2
43.8
50
11
C25.0
ICD-10 Finland
Malignant neoplasm: Head of pancreas
115.5
42.0
44
5
WX302
NOMESCO Finland
Thoracal epidural anesthesy
18.9
40.0
64
51
H01CB02
ATC
octreotide; parenteral
441.0
37.4
36
*
JLC11
NOMESCO Finland
Laparoscopic distal pancreatectomy
+∞
35.6
33
*
C25.2
ICD-10 Finland
Malignant neoplasm: Tail of pancreas
389.7
33.0
32
*
D13.7
ICD-10 Finland
Benign neoplasm: Endocrine pancreas
200.6
32.9
33
*
D13.6
ICD-10 Finland
Benign neoplasm: Pancreas
128.9
30.8
32
*
JN3BD
NOMESCO Finland
Extensive abdominal CT
10.2
30.7
67
99
JN5ER
NOMESCO Finland
PET-CT of receptors in whole body
124.0
29.7
31
*
L01BC06
ATC
capecitabine; oral
20.3
29.7
45
29
JN7AQ
NOMESCO Finland
Somatostatin receptor SPET med low dose CT
178.7
29.6
30
*
C78.7
ICD-10 Finland
Secondary malignant neoplasm of liver and intrahepatic bile duct
26.7
29.0
40
19
D76
ICPC
Malignant neoplasm pancreas
114.5
27.5
29
*
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
26.4
27.5
38
18
D44.8
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Pluriglandular involvement
+∞
25.6
24
*
JN3CD
NOMESCO Finland
Abdominal CT examination both without and with contrast
16.2
25.0
41
32
E34.0
ICD-10 Finland
Carcinoid syndrome
+∞
24.5
23
*
XX7JT
NOMESCO Finland
Somatostatin isotope ablative therapy
+∞
24.5
23
*
JLC30
NOMESCO Finland
Pancreatoduodenectomy
144.2
24.2
25
*
A04AA02
ATC
granisetron; systemic, transdermal
10.4
22.9
47
59
JN4BD
NOMESCO Finland
Extensive body CT
7.9
22.7
57
100
A03FA01
ATC
metoclopramide; systemic, rectal
5.7
22.6
79
216
JN3AD
NOMESCO Finland
Abdominal CT examination
9.7
22.4
48
65
JN1DG
NOMESCO Finland
Very extensive MRI examination of upper part of abdomen with high intensity magnet
25.4
21.7
30
14
XX9AN
NOMESCO Finland
Complementary isotope examination or additional picture
+∞
21.3
20
*
JN4CD
NOMESCO Finland
Very extensive body CT
11.8
20.7
39
41
E13.9
ICD-10 Finland
Other specified diabetes mellitus, without complications
45.7
20.1
24
6
JMA10
NOMESCO Finland
Transabdominal total splenectomy
118.1
20.0
21
*
JN1CG
NOMESCO Finland
Extensive MRI examination of upper part of abdomen with high intensity magnet
18.9
19.1
29
18
XJD02
NOMESCO Finland
Peroral endoscopic ultrasonography
211.0
18.9
19
*
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
7.2
18.8
49
89
JJ2AT
NOMESCO Finland
Biopsy of liver with ultrasound guidance
17.9
18.7
29
19
JN4AD
NOMESCO Finland
Body CT examination
8.0
18.4
44
70
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
9.5
18.3
39
51
JL1AT
NOMESCO Finland
Biopsy of pancreas with ultrasound guidance
+∞
18.0
17
*
197
Kela drug reimbursment
Sunitinib
+∞
18.0
17
*
158
Kela drug reimbursment
Everolimus
+∞
18.0
17
*
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
8.6
17.0
38
54
TPH07
NOMESCO Finland
Cathetrisation of artery
5.9
16.9
52
116
D37.9
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Digestive organ, unspecified
99.4
16.9
18
*
JLC00
NOMESCO Finland
Excision of lesion of pancreas
+∞
15.9
15
*
8249/3-C25.2
ICD-O-3
Neuroendocrine tumor, grade 2 of tail of pancreas
+∞
15.9
15
*
WX602
NOMESCO Finland
Repeated or continuing anesthesia shots throug a catheter
6.8
15.8
42
77
8246/3-C25.9
ICD-O-3
Neuroendocrine carcinoma, NOS, of pancreas, NOS
+∞
14.8
14
*
C25.8
ICD-10 Finland
Malignant neoplasm: Overlapping lesion of pancreas
+∞
14.8
14
*
B01AB05
ATC
enoxaparin; parenteral
3.7
14.6
88
371
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
8.5
14.0
31
43
WZC30
NOMESCO Finland
Teaching
4.7
13.9
52
142
JJ1CE
NOMESCO Finland
Liver, bile duct and pancreas endoscopic ultrasound examination
+∞
13.7
13
*
BBA70
NOMESCO Finland
Implantation or transplantation of parathyroid gland
+∞
13.7
13
*
E21.09
ICD-10 Finland
Other primary hyperparathyroidism
23.4
13.6
19
9
WX408
NOMESCO Finland
General anesthesy, balanced
3.5
13.3
81
340
AA4CG
NOMESCO Finland
Extensive MRI examination of sella turcica with high intensity magnet
54.1
13.0
15
*
JN7AN
NOMESCO Finland
Somatostatin receptor isotope imaging
+∞
12.6
12
*
L01XE10
ATC
[U] everolimus; oral
+∞
12.6
12
*
JN3DG
NOMESCO Finland
Very extensive MRI examination with high intensity magnet
+∞
12.6
12
*
C25.1
ICD-10 Finland
Malignant neoplasm: Body of pancreas
139.2
12.6
13
*
WD305
NOMESCO Finland
Simple therapy of methastized malignancy with biomodifiers
23.3
12.3
17
8
103
Kela drug reimbursment
Diabetes, insulin-treated
3.4
11.9
74
307
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
4.4
11.8
47
135
8240/3-C25.2
ICD-O-3
Neuroendocrine tumor, NOS, of tail of pancreas
+∞
11.6
11
*
340
Kela drug reimbursment
Everolimus
+∞
11.6
11
*
JMA11
NOMESCO Finland
Laparoscopic total splenectomy
127.8
11.6
12
*
GD1AA
NOMESCO Finland
Thorax X-ray examination
3.0
11.3
105
572
215
Kela drug reimbursment
Diabetes, non-insulin-treated
3.3
11.2
69
284
JAH01
NOMESCO Finland
Laparoscopy
9.9
11.1
22
25
N02AA05
ATC
oxycodone; systemic
4.0
10.8
47
146
T73
ICPC
Neoplasm endocrine other/unspecified
+∞
10.5
10
*
L01XE04
ATC
[U] sunitinib; oral
+∞
10.5
10
*
JN1BD
NOMESCO Finland
Extensive CT examination of upper part of abdomen
34.8
10.5
13
*
601
Kela drug reimbursment
Severe malabsorption of nutrients, mainly fats
25.1
10.4
14
6
WD225
NOMESCO Finland
Demanding therapy of methastized malignancy with hormones
25.1
10.4
14
6
T90
ICPC
Diabetes non-insulin dependent
3.2
10.0
64
267
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
2.9
10.0
81
396
JN1CD
NOMESCO Finland
Very extensive CT examination of upper part of abdomen
27.8
10.0
13
5
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.9
9.7
76
361
WZC00
NOMESCO Finland
Planning of intervention or health care consultation
2.9
9.6
79
386
E16.10
ICD-10 Finland
Hyperinsulinism
105.3
9.5
10
*
JKA20
NOMESCO Finland
Cholecystectomy
9.1
9.3
19
23
E11.9
ICD-10 Finland
Type 2 diabetes mellitus, without complications
3.1
9.1
59
246
JAH00
NOMESCO Finland
Laparotomy
9.4
9.0
18
21
A10AE04
ATC
insulin glargine; parenteral
4.2
8.9
35
98
A10AB05
ATC
insulin aspart; parenteral (insulins and analog. for injection, fast-acting)
5.0
8.7
28
64
E16.2
ICD-10 Finland
Hypoglycaemia, unspecified
17.4
8.7
13
8
A04AA01
ATC
ondansetron; systemic, rectal
5.3
8.7
26
55
106
Kela drug reimbursment
Hypoparathyroidism
+∞
8.4
8
*
322
Kela drug reimbursment
Sunitinib
+∞
8.4
8
*
8249/3-C25.0
ICD-O-3
Neuroendocrine tumor, grade 2 of head of pancreas
+∞
8.4
8
*
SPAT1262
SPAT
Handing over of treatment supplies
3.1
8.3
52
209
WD115
NOMESCO Finland
Multiple cystostatic therapy of methastized malignancy
12.5
8.2
14
12
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
3.2
8.1
47
178
UJK02
NOMESCO Finland
ERCP
9.1
8.0
16
19
JL5AG
NOMESCO Finland
Simple MRI examinaiton of bile and pancreas ducts with high intesity magnet
47.0
7.8
9
*
JL5SB
NOMESCO Finland
Endoscopic retrograd cholangiopancreaticography
12.6
7.7
13
11
JN3CG
NOMESCO Finland
Extensive MRI examination of abdomen with high intensity magnet
26.3
7.7
10
*
JN4DD
NOMESCO Finland
Scout CT scan of torso
83.3
7.5
8
*
A10BA02
ATC
metformin; oral
2.6
7.5
65
321
JL2AT
NOMESCO Finland
Cytology of pancreas with ultrasound guidance
+∞
7.3
7
*
BBA50
NOMESCO Finland
Total parathyroidectomy
+∞
7.3
7
*
8249/3-C25.1
ICD-O-3
Neuroendocrine tumor, grade 2 of body of pancreas
+∞
7.3
7
*
JLC40
NOMESCO Finland
Total pancreatoduodenectomy
+∞
7.3
7
*
D35.2
ICD-10 Finland
Benign neoplasm: Pituitary gland
16.6
7.3
11
7
A79
ICPC
Malignancy NOS
21.0
7.2
10
5
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
7.2
7.0
16
24
JDW98
NOMESCO Finland
Other transluminal endoscopic operation on stomach or duodenum
14.5
7.0
11
8
D37.6
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Liver, gallbladder and bile ducts
8.8
7.0
14
17
XX3DW
NOMESCO Finland
Time consuming IT work
3.5
6.9
32
104
BBA40
NOMESCO Finland
Subtotal parathyroidectomy
41.6
6.8
8
*
A11CC03
ATC
alfacalcidol; systemic
8.3
6.7
14
18
R10.0
ICD-10 Finland
Acute abdomen
8.3
6.7
14
18
K86.9
ICD-10 Finland
Disease of pancreas, unspecified
23.5
6.7
9
*
FB1BD
NOMESCO Finland
Extensive CT examination of arteria pulmonalis
4.2
6.7
25
67
E14.9
ICD-10 Finland
Unspecified diabetes mellitus, without complications
12.9
6.7
11
9
B01AB10
ATC
tinzaparin; parenteral
4.4
6.6
23
58
E13.8
ICD-10 Finland
Other specified diabetes mellitus, with unspecified complications
72.2
6.5
7
*
E89.2
ICD-10 Finland
Postprocedural hypoparathyroidism
72.2
6.5
7
*
E21.0
ICD-10 Finland
Primary hyperparathyroidism
8.7
6.4
13
16
J01MA12
ATC
levofloxacin; systemic
2.7
6.4
48
215
K90.3
ICD-10 Finland
Pancreatic steatorrhoea
18.8
6.3
9
5
V03AH01
ATC
diazoxide; systemic
+∞
6.3
6
*
8246/3-C25.2
ICD-O-3
Neuroendocrine carcinoma, NOS, of tail of pancreas
+∞
6.3
6
*
JN5DR
NOMESCO Finland
PET-CT of upper body metabolism
9.1
6.2
12
14
TPH04
NOMESCO Finland
Cathetrisation of vein
2.6
6.1
49
228
Z51.5
ICD-10 Finland
Palliative care
4.3
6.0
21
53
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
162
24
358.66
307.65
9.8
2.5
45.0
3.0
nmol/l
0.69
162
24
70
42
25.17
88.40
2.0
1.5
198.5
272.5
ug/g
1.36
59
26
58
22
36.80
87.40
4.4
1.4
27.1
16.4
ug/l
1.28
58
22
100
181
10.10
59.99
3.6
4.6
5.2
30.5
ug/l
0.56
81
151
47
35
17.27
52.04
2.2
1.1
0.7
0.7
nmol/l
0.02
47
30
59
69
11.73
49.15
3.3
3.2
715.9
148.7
u/ml
0.38
54
57
136
555
5.58
30.52
5.3
2.7
75.3
55.7
u/l
0.53
130
516
156
719
6.41
30.02
10.5
4.9
34.7
35.4
g/l
0.93
151
674
146
744
4.61
21.85
11.8
6.0
1.2
1.2
mmol/l
0.57
141
675
152
810
4.71
21.07
14.4
7.3
1.2
1.2
mmol/l
0.48
124
691
58
162
4.64
19.74
3.9
2.6
126.6
30.9
u/l
0.95
53
135
164
993
4.70
17.42
9.2
4.9
7.3
6.7
mmol/l
2.92
159
933
65
216
3.98
17.32
4.7
3.1
8.5
8.0
umol/l
0.07
57
193
137
771
3.49
15.41
5.9
4.1
—
—
—
0
0
44
123
4.31
14.66
6.0
3.8
60.7
84.0
ng/l
1.46
37
109
102
544
2.80
11.51
10.5
3.5
2.4
2.4
mmol/l
0.29
96
466
147
987
2.87
9.98
21.6
9.3
4.2
4.1
e9/l
0.25
138
876
34
104
3.74
9.84
11.4
7.8
25.3
24.9
mmol/l
0.41
34
99
35
117
3.42
8.84
3.7
3.6
136.8
242.7
ng/l
1.06
28
105
47
191
2.91
8.54
8.4
8.2
1.8
1.1
mmol/l
0.50
41
158
53
233
2.74
8.30
2.5
2.4
18.6
22.4
%
1.25
45
201
46
192
2.82
7.92
8.5
8.0
5.3
5.2
kpa
0.37
46
186
46
192
2.82
7.92
8.5
8.0
13.7
11.9
kpa
1.21
46
187
74
395
2.39
7.65
2.5
2.4
—
—
—
0
0
94
598
2.08
6.00
3.2
3.0
—
—
—
0
0
56
293
2.27
5.86
8.2
2.9
2.5
2.4
mmol/l
1.37
49
254
14
33
4.49
5.66
1.0
1.3
—
—
—
0
0
11
22
5.23
5.32
1.7
1.5
—
—
—
0
0
82
523
1.97
4.98
3.3
3.3
726.0
1105.5
ng/l
0.66
73
426
15
42
3.78
4.87
1.9
1.5
—
—
—
0
0
147
1154
2.05
4.72
6.0
3.3
89.3
53.8
u/l
1.16
141
1082
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
16
48
3.54
4.71
1.6
2.4
0.3
0.4
u/ml
—
9
27
36
175
2.29
4.40
5.3
3.2
—
—
—
0
0
65
398
1.94
4.35
2.7
2.0
3.0
3.3
mg/l
0.27
57
338
72
471
1.83
3.86
3.2
3.0
0.4
0.6
e6/l
0.41
57
341
7
8
9.01
3.80
1.6
1.8
29.4
29.1
umol/l
—
7
8
58
369
1.81
3.34
1.9
1.8
1.5
1.4
mg/l
0.29
46
296
24
112
2.30
3.22
1.9
1.6
—
—
—
0
0
8
16
5.16
3.08
1.4
1.2
—
—
—
0
0
65
442
1.70
2.93
4.0
3.6
0.0
0.0
estimate
0.00
25
149
86
630
1.64
2.91
4.2
3.6
—
—
—
0
0
184
1663
2.41
2.85
33.9
14.6
35.0
23.9
mg/l
3.85
170
1308
27
143
2.03
2.67
6.9
3.1
74.7
63.1
ml/min/173m2
1.42
15
64
91
690
1.59
2.61
4.2
3.9
37.7
47.9
ng/l
0.23
72
497
52
348
1.67
2.44
1.6
1.7
463.1
450.9
pmol/l
0.07
42
289
86
661
1.53
2.24
2.2
2.0
87.4
94.6
pmol/l
0.81
55
350
8
24
3.43
2.20
1.3
1.4
—
—
—
0
0
7
19
3.78
2.17
1.3
1.4
—
—
—
0
0
6
14
4.38
2.16
1.3
1.4
—
—
—
0
0
11
44
2.59
2.05
1.4
1.2
—
—
—
0
0
175
1601
1.77
1.88
29.9
13.3
82.6
80.6
ml/min/173m2
0.70
166
1324
19
104
1.91
1.74
1.8
1.4
—
—
—
0
0
11
48
2.37
1.74
1.3
1.7
—
—
—
0
0
11
48
2.37
1.74
1.3
1.7
—
—
—
0
0
30
191
1.67
1.69
1.6
2.1
—
—
—
0
0
97
797
1.42
1.67
4.0
3.5
0.0
0.0
estimate
0.00
29
156
97
799
1.42
1.64
5.2
4.7
0.0
0.0
estimate
0.00
28
158
140
1232
1.46
1.64
5.2
3.8
14.5
14.8
pmol/l
0.48
134
1088
30
194
1.64
1.60
1.7
2.1
—
—
—
0
0
98
813
1.40
1.57
4.0
3.5
0.0
0.0
estimate
0.00
27
150
5
15
3.39
1.53
1.2
1.3
—
—
—
0
0
39
275
1.52
1.46
1.7
2.1
—
—
—
0
0
25
160
1.64
1.40
3.8
4.0
1.8
1.7
mmol/l
0.05
19
123
43
313
1.48
1.39
3.7
3.8
129.1
165.6
ng/l
0.18
30
248
25
164
1.60
1.28
3.8
4.0
5.7
5.7
kpa
0.04
25
159
7
143
0.47
1.26
2.0
1.8
—
—
—
0
0
43
319
1.44
1.26
1.9
1.7
1186.7
1166.3
nmol/l
0.05
37
241
38
276
1.47
1.24
2.7
3.0
1.8
2.1
e6/l
0.13
18
144
165
1528
1.47
1.22
5.6
4.5
2.0
1.9
mu/l
0.27
152
1370
139
1251
1.37
1.22
3.5
4.1
13.5
11.6
mm/h
0.57
124
1139
5
20
2.54
1.16
1.2
1.2
—
—
—
0
0
174
1635
1.51
1.12
7.5
4.6
6.8
6.0
mmol/l
6.91
168
1491
21
137
1.60
1.11
4.1
2.8
4.7
4.2
kpa
0.37
21
131
7
33
2.16
1.06
3.6
8.9
—
176.4
—
0
7
7
34
2.10
1.04
1.3
1.6
—
—
—
0
0
7
35
2.04
1.01
1.6
1.5
—
—
—
0
0
18
116
1.61
1.00
6.6
3.7
5.5
5.1
kpa
1.10
18
106
0
31
0.00
0.97
0.0
1.2
—
—
—
0
0
160
1494
1.36
0.94
30.2
15.5
38.4
39.9
%
1.43
117
1077
13
78
1.71
0.94
3.1
3.9
24.6
24.1
mmol/l
0.16
13
69
44
346
1.35
0.93
4.3
3.6
1.0
1.0
kg/l
2.06
11
41
17
251
0.65
0.92
1.1
1.2
1.5
12.1
u/ml
—
9
100
8
43
1.90
0.88
6.3
2.5
26.2
25.5
mmol/l
—
8
35
8
43
1.90
0.88
1.8
1.2
—
—
—
0
0
6
31
1.96
0.85
1.7
1.5
—
—
—
0
0
0
26
0.00
0.79
0.0
1.1
—
—
—
0
0
14
91
1.58
0.77
2.9
2.5
0.9
1.3
%
1.07
14
91
38
301
1.32
0.77
2.5
2.7
0.8
1.0
e6/l
0.30
18
167
0
28
0.00
0.76
0.0
1.2
—
294.1
—
0
14
5
24
2.11
0.75
1.2
1.8
—
—
—
0
0
7
39
1.82
0.73
1.6
1.5
—
—
—
0
0
52
445
1.23
0.58
2.3
2.8
354.4
7726.5
umol/l
1.98
46
380
8
125
0.63
0.56
3.0
1.6
—
—
—
0
0
13
91
1.46
0.54
6.5
10.6
25.5
24.6
mmol/l
0.27
13
86
9
132
0.67
0.54
3.0
1.7
—
—
—
0
0
6
40
1.52
0.52
1.2
1.9
—
—
—
0
0
19
146
1.33
0.49
2.4
2.5
5.7
8.1
ug/l
0.33
19
127
0
15
0.00
0.41
0.0
1.0
—
—
—
0
0
0
16
0.00
0.41
0.0
1.2
—
—
—
0
0
0
17
0.00
0.41
0.0
1.3
—
—
—
0
0
9
68
1.34
0.38
1.0
1.9
—
—
—
0
0
23
276
0.81
0.37
1.0
1.2
15.8
39.1
iu/ml
—
7
93
24
200
1.23
0.35
1.7
1.3
—
—
—
0
0
36
410
0.85
0.34
2.5
3.1
0.9
0.8
ug/l
0.27
22
265
10
74
1.37
0.33
8.6
4.5
24.9
25.2
mmol/l
—
10
68
7
55
1.28
0.30
1.6
1.7
—
—
—
0
0
172
1680
1.18
0.29
5.0
5.2
2.5
2.8
mmol/l
3.80
163
1548
5
75
0.66
0.26
1.0
1.3
—
—
—
0
0
5
38
1.32
0.23
1.2
1.4
—
—
—
0
0
0
11
0.00
0.21
0.0
2.2
—
—
—
0
0
0
11
0.00
0.21
0.0
1.9
—
—
—
0
0
0
11
0.00
0.21
0.0
2.5
—
48.2
—
0
11
0
11
0.00
0.21
0.0
1.3
—
—
—
0
0
0
11
0.00
0.21
0.0
1.9
—
—
—
0
0
0
11
0.00
0.21
0.0
2.2
—
—
—
0
0
0
11
0.00
0.21
0.0
1.6
—
—
—
0
0
0
11
0.00
0.21
0.0
1.3
—
—
—
0
0
0
10
0.00
0.21
0.0
1.5
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.5
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
2.3
—
—
—
0
0
0
12
0.00
0.21
0.0
2.3
—
—
—
0
0
0
12
0.00
0.21
0.0
2.2
—
—
—
0
0
0
12
0.00
0.21
0.0
2.3
—
—
—
0
0
0
12
0.00
0.21
0.0
2.1
—
—
—
0
0
0
13
0.00
0.21
0.0
2.5
—
13.4
—
0
13
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
6
50
1.21
0.20
2.7
3.7
—
4.0
—
0
5
6
50
1.21
0.20
1.3
1.6
—
—
—
0
0
163
1599
1.11
0.18
4.4
4.1
1.4
1.3
mmol/l
0.96
156
1468
7
60
1.17
0.18
2.1
3.3
—
—
—
0
0
5
67
0.74
0.17
1.4
2.2
—
—
—
0
0
168
1652
1.11
0.16
4.8
4.6
4.3
4.6
mmol/l
4.43
162
1533
167
1643
1.10
0.15
4.6
4.6
1.4
1.4
mmol/l
1.51
161
1513
70
675
1.06
0.11
3.9
5.2
2.0
2.6
ug/l
0.50
62
612
101
987
1.05
0.09
2.9
3.0
—
—
—
0
0
5
64
0.78
0.08
1.4
1.9
—
—
—
0
0
7
81
0.86
0.07
1.1
1.1
—
—
—
0
0
25
264
0.94
0.06
1.3
1.5
—
—
—
0
0
36
348
1.04
0.04
1.6
1.2
2.7
1.8
u/ml
0.23
13
102
53
542
0.97
0.04
3.1
4.4
26.0
20.9
%
1.34
27
258
22
225
0.98
0.00
3.8
4.7
33.7
31.9
%
0.23
16
150
22
215
1.03
0.00
16.5
8.2
—
—
—
0
0
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
7.1
—
—
—
0
0
0
9
0.00
0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
9.9
—
0
6
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.7
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
99.0
—
0
5
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.4
—
—
—
0
0
9
95
0.94
0.00
1.0
1.9
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: C3_PANCREAS_NEUROENDOCRINE – Neuroendocrine tumor and carcinoma of pancreas
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).